What Happened?
South San Francisco, CA-based Sonoma-BioTherapeutics Appointed Jeffrey Bluestone as President and Chief Executive Officer
About the Company
Sonoma Biotherapeutics is inventing the future of living therapies for autoimmune disease — safe, effective treatments as unique as each individual patient. Regulatory T cell therapies that harness a patient`s own immune cells, powerful next generation gene editing techniques and advanced manufacturing and quality assurance processes. Sonoma`s mission is to create a best-in-class regulatory T cell therapy that delivers long-lasting, highly efficacious treatments leading to cures across a spectrum of autoimmune and degenerative diseases.
About the Person
Jeffrey Bluestone is President and Chief Executive Officer at Sonoma BioTherapeutics. Previously, Jeffrey held various senior HR leadership roles in the industry.
Info Source
News
Short Profile